PT728214E - Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado - Google Patents

Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado

Info

Publication number: PT728214E
Authority: PT; Portugal
Prior art keywords: pct; aav; cell lines; express; additional
Prior art date: 1993-11-09

Application number

PT95900505T

Other languages

English (en)

Inventor

James P Trempe

Qicheng Yang

Original Assignee

Ohio Med College

Targeted Genetics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-09

Filing date

1994-11-03

Publication date

2004-11-30

1994-11-03 Application filed by Ohio Med College, Targeted Genetics Corp filed Critical Ohio Med College

2004-11-30 Publication of PT728214E publication Critical patent/PT728214E/pt

Links

108090000623 proteins and genes Proteins 0.000 title abstract 2
230000029812 viral genome replication Effects 0.000 title 1
239000013607 AAV vector Substances 0.000 abstract 2
238000004806 packaging method and process Methods 0.000 abstract 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 abstract 1
101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 abstract 1
102000003792 Metallothionein Human genes 0.000 abstract 1
108090000157 Metallothionein Proteins 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
101150066583 rep gene Proteins 0.000 abstract 1
230000035897 transcription Effects 0.000 abstract 1
238000013518 transcription Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT95900505T 1993-11-09 1994-11-03 Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado PT728214E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15106593A	1993-11-09	1993-11-09
US27356394A	1994-07-11	1994-07-11

Publications (1)

Publication Number	Publication Date
PT728214E true PT728214E (pt)	2004-11-30

Family

ID=26848297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT95900505T PT728214E (pt)	1993-11-09	1994-11-03	Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado

Country Status (11)

Country	Link
US (1)	US5837484A (pt)
EP (1)	EP0728214B1 (pt)
JP (1)	JP3952312B2 (pt)
AT (1)	ATE272123T1 (pt)
AU (1)	AU678867B2 (pt)
CA (1)	CA2176215C (pt)
DE (1)	DE69433922T2 (pt)
DK (1)	DK0728214T3 (pt)
ES (1)	ES2220923T3 (pt)
PT (1)	PT728214E (pt)
WO (1)	WO1995013392A1 (pt)

Families Citing this family (297)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5436146A (en) *	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
WO1995013365A1 (en) *	1993-11-09	1995-05-18	Targeted Genetics Corporation	Generation of high titers of recombinant aav vectors
ATE386131T1 (de)	1994-04-13	2008-03-15	Univ Rockefeller	Aav-vermittelte überbringung von dna in zellen des nervensystems
US5658785A (en) *	1994-06-06	1997-08-19	Children's Hospital, Inc.	Adeno-associated virus materials and methods
US20020159979A1 (en)	1994-06-06	2002-10-31	Children's Hospital, Inc.	Adeno-associated virus materials and methods
JPH10507352A (ja) *	1994-10-13	1998-07-21	ドイチェスクレブスフォルシュンクスツェントルムスチフトゥングデスエッフェントリヒェンレヒツ	ｒｅｐ陰性ＡＡＶ変異体の調製およびそれに使用可能な細胞
US5856152A (en) *	1994-10-28	1999-01-05	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV vector and methods of use therefor
US6342390B1 (en)	1994-11-23	2002-01-29	The United States Of America As Represented By The Secretary Of Health And Human Services	Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US6326356B1 (en)	1996-10-18	2001-12-04	Board Of Regents, The University Of Texas System	Suppression of neu overexpression using a mini-E1A gene
CA2207927A1 (en) *	1994-12-06	1996-06-13	Targeted Genetics Corporation	Packaging cell lines for generation of high titers of recombinant aav vectors
US6924128B2 (en)	1994-12-06	2005-08-02	Targeted Genetics Corporation	Packaging cell lines for generation of high titers of recombinant AAV vectors
US5843742A (en) *	1994-12-16	1998-12-01	Avigen Incorporated	Adeno-associated derived vector systems for gene delivery and integration into target cells
EA001616B1 (ru)	1995-02-28	2001-06-25	Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ	Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US6752987B1 (en)	1995-02-28	2004-06-22	The Regents Of The University Of California	Adenovirus encoding human adenylylcyclase (AC) VI
US5756283A (en) *	1995-06-05	1998-05-26	The Trustees Of The University Of Pennsylvania	Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en)	1995-06-05	2001-08-28	The Trustees Of The University Of Pennsylvania	Adenovirus gene therapy vehicle and cell line
US6093570A (en) *	1995-06-07	2000-07-25	The University Of North Carolina At Chapel Hill	Helper virus-free AAV production
WO1997006272A2 (en) *	1995-08-03	1997-02-20	Avigen, Inc.	High efficiency helper system for aav vector production
US5622856A (en) *	1995-08-03	1997-04-22	Avigen	High efficiency helper system for AAV vector production
US6001650A (en)	1995-08-03	1999-12-14	Avigen, Inc.	High-efficiency wild-type-free AAV helper functions
US6162796A (en) *	1995-09-27	2000-12-19	The Rockefeller University	Method for transferring genes to the heart using AAV vectors
US6086913A (en) *	1995-11-01	2000-07-11	University Of British Columbia	Liposomal delivery of AAV vectors
US6004797A (en) *	1995-11-09	1999-12-21	Avigen, Inc.	Adenovirus helper-free recombinant AAV Virion production
US20020193580A1 (en) *	1995-12-15	2002-12-19	Mitchell Lloyd G.	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) *	1995-12-15	2006-04-27	Mitchell Lloyd G	Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) *	1995-12-15	2003-02-06	Mitchell Lloyd G.	Methods and compositions for use in spliceosome mediated RNA trans-splicing
DE19608751B4 (de)	1996-03-06	2006-05-18	Medigene Ag	Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
US5952221A (en) *	1996-03-06	1999-09-14	Avigen, Inc.	Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6294370B1 (en)	1997-06-24	2001-09-25	Medigene Ag	System for the production of AAV vectors
US6541012B2 (en)	1996-06-24	2003-04-01	Christoph Bogedain	System for the production of AAV vectors
DE19625188A1 (de) *	1996-06-24	1998-01-08	Medigene Gmbh	System zur Herstellung von AAV-Vektoren
AU722375B2 (en) *	1996-09-06	2000-08-03	Trustees Of The University Of Pennsylvania, The	Methods using cre-lox for production of recombinant adeno-associated viruses
US5866552A (en) *	1996-09-06	1999-02-02	The Trustees Of The University Of Pennsylvania	Method for expressing a gene in the absence of an immune response
EP0931158A1 (en) *	1996-09-06	1999-07-28	The Trustees Of The University Of Pennsylvania	An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
CA2272578A1 (en) *	1996-11-18	1998-05-28	Mcgill University	Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
JP2001506133A (ja) *	1996-12-18	2001-05-15	ターゲティッドジェネティクスコーポレイション	組換えａａｖベクターの産生における使用のための、ａａｖスプリット−パッケージング遺伝子およびこのような遺伝子を含む細胞株
US6548286B1 (en) *	1997-04-14	2003-04-15	Cell Genesys, Inc.	Methods for increasing the efficiency of recombinant AAV product
US6251677B1 (en)	1997-08-25	2001-06-26	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV virus and methods of use thereof
US6989264B2 (en)	1997-09-05	2006-01-24	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en)	1997-09-05	2003-05-20	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DK1009808T3 (da)	1997-09-05	2013-01-21	Genzyme Corp	Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6642051B1 (en) *	1997-10-21	2003-11-04	Targeted Genetics Corporation	Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
US6346415B1 (en) *	1997-10-21	2002-02-12	Targeted Genetics Corporation	Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
IT1297074B1 (it) *	1997-11-21	1999-08-03	Angeletti P Ist Richerche Bio	Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
US6953690B1 (en)	1998-03-20	2005-10-11	The Trustees Of The University Of Pennsylvania	Compositions and methods for helper-free production of recombinant adeno-associated viruses
EP1930418B1 (en)	1998-09-04	2015-04-08	Genzyme Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1939215A1 (en)	1998-10-22	2008-07-02	The University of Montana	Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
US6303362B1 (en)	1998-11-19	2001-10-16	The Board Of Trustees Of The Leland Stanford Junior University	Adenoviral vector and methods for making and using the same
US6387368B1 (en)	1999-02-08	2002-05-14	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV virus and methods of use thereof
US6893865B1 (en)	1999-04-28	2005-05-17	Targeted Genetics Corporation	Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6793926B1 (en) *	1999-05-27	2004-09-21	Genovo, Inc.	Methods for production of a recombinant adeno-associated virus
DK1180159T3 (da)	1999-05-28	2008-11-17	Targeted Genetics Corp	Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
EP1939300A1 (en)	1999-05-28	2008-07-02	Targeted Genetics Corporation	Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
EP1916258B1 (en)	1999-08-09	2014-04-23	Targeted Genetics Corporation	Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
CA2379166C (en)	1999-08-09	2013-03-26	Targeted Genetics Corporation	Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
AU7739000A (en)	1999-10-01	2001-05-10	University Of Florida	Temperature-sensitive regulation of viral vector production
US7115391B1 (en) *	1999-10-01	2006-10-03	Genovo, Inc.	Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
JP2003511082A (ja) *	1999-10-12	2003-03-25	ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル	第ｖｉｉｉ因子をコードするアデノ随伴ウィルスベクターとその使用法
EP1255822A2 (en)	1999-12-27	2002-11-13	The Regents Of The University Of California	Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
US6916635B2 (en) *	2000-10-02	2005-07-12	The Research Foundation Of State University Of New York	Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
US20040126774A1 (en) *	2001-01-08	2004-07-01	Mitchell Lioyd G.	Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
US6844192B2 (en)	2001-06-29	2005-01-18	Wake Forest University	Adenovirus E4 protein variants for virus production
WO2003025161A1 (en)	2001-09-18	2003-03-27	Clontech Laboratories, Inc.	Site-specific recombinase based method for producing adenoviral vectors
US7399753B2 (en) *	2002-02-25	2008-07-15	Virxsys Corporation	Trans-splicing mediated photodynamic therapy
AU2003223214B2 (en) *	2002-03-01	2008-09-18	Celltech R & D, Inc.	Methods to increase or decrease bone density
JP2005536231A (ja) *	2002-05-08	2005-12-02	イントロン，インコーポレーテッド	アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
EP1579004B1 (en) *	2002-10-23	2010-06-16	VIRxSYS Corporation	Screening methods for identification of efficient pre-trans-splicing molecules
ES2371913T3 (es)	2003-01-22	2012-01-11	Duke University	Constructos mejorados para expresar polipéptidos lisosomales.
US7510872B2 (en) *	2003-02-26	2009-03-31	Nationwide Children's Hospital	Recombinant adeno-associated virus production
EP1716165A4 (en) *	2004-01-23	2008-06-18	Virxsys Corp	EXPRESSION OF APOA-1 AND VARIANTS THEREOF, USING SPSSISSOSOM-MEDIATED RNA TRANS MIXING
US7968334B2 (en) *	2004-01-23	2011-06-28	Virxsys Corporation	Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US8053232B2 (en) *	2004-01-23	2011-11-08	Virxsys Corporation	Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
EP1723227A4 (en)	2004-02-10	2007-09-19	Dartmouth College	NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
US20060094110A1 (en) *	2004-07-30	2006-05-04	Mcgarrity Gerard J	Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) *	2004-08-09	2006-06-22	Garcia-Blanco Mariano A	Use of RNA trans-splicing for generation of interfering RNA molecules
US7166963B2 (en) *	2004-09-10	2007-01-23	Axcelis Technologies, Inc.	Electrodeless lamp for emitting ultraviolet and/or vacuum ultraviolet radiation
DE102004047492B4 (de) *	2004-09-23	2006-07-20	Jost-Werke Gmbh & Co. Kg	Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
US7871795B2 (en)	2004-10-08	2011-01-18	Virxsys Corporation	Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
EP1831365B1 (en) *	2004-10-08	2013-08-07	VIRxSYS Corporation	Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
EP2097095B1 (en)	2006-11-29	2016-01-27	Nationwide Children's Hospital	Myostatin inhibition for enhancing muscle and/or improving muscle function
US9415121B2 (en)	2008-12-19	2016-08-16	Nationwide Children's Hospital	Delivery of MECP2 polynucleotide using recombinant AAV9
US11219696B2 (en)	2008-12-19	2022-01-11	Nationwide Children's Hospital	Delivery of polynucleotides using recombinant AAV9
US20120093775A1 (en)	2009-03-27	2012-04-19	Proyecto De Biomedicina Cima, S.L.	Methods and compositions for the treatment of cirrhosis and liver fibrosis
HRP20250897T1 (hr)	2009-05-02	2025-09-26	Genzyme Corporation	Genska terapija za neurodegenerativne poremećaje
BR112012010755A2 (pt)	2009-11-05	2015-09-22	Proyecto Biomedicina Cima Sl	constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
WO2012071559A2 (en)	2010-11-23	2012-05-31	Presage Biosciences, Inc.	Therapeutic methods and compositions for solid delivery
US20140155469A1 (en)	2011-04-19	2014-06-05	The Research Foundation Of State University Of New York	Adeno-associated-virus rep sequences, vectors and viruses
US10196636B2 (en)	2011-04-21	2019-02-05	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of myotilin
WO2012145597A2 (en)	2011-04-21	2012-10-26	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of myotilin
US20130039888A1 (en)	2011-06-08	2013-02-14	Nationwide Children's Hospital Inc.	Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
EP2736539B1 (en)	2011-07-25	2017-08-23	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of dux4
US9434928B2 (en)	2011-11-23	2016-09-06	Nationwide Children's Hospital, Inc.	Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
US9163259B2 (en)	2012-05-04	2015-10-20	Novartis Ag	Viral vectors for the treatment of retinal dystrophy
AU2013296425B2 (en)	2012-08-01	2018-06-07	Nationwide Children's Hospital	Intrathecal delivery of recombinant adeno-associated virus 9
US9539307B2 (en)	2012-09-17	2017-01-10	The Research Institute At Nationwide Children's Hospital	Compositions and methods for treating amyotrophic lateral sclerosis
CA2908253C (en)	2013-04-04	2024-01-09	Trustees Of Dartmouth College	Compositions and methods for in vivo excision of hiv-1 proviral dna
WO2014168953A1 (en)	2013-04-08	2014-10-16	University Of Iowa Research Foundation	Chimeric adeno-associated virus/ bocavirus parvovirus vector
MX388221B (es)	2013-04-20	2025-03-19	Res Institute At Nationwide Children´S Hospital	ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
CN115120746A (zh)	2013-05-15	2022-09-30	明尼苏达大学董事会	腺相关病毒介导的基因向中枢神经系统转移
SI3702466T1 (sl)	2013-08-27	2023-04-28	Research Institute At Nationwide Children's Hospital	Proizvodi in postopki za zdravljenje amiotrofične lateralne skleroze
US9725719B2 (en)	2013-11-05	2017-08-08	The Research Institute At Nationwide Children's Hospital	Compositions and methods for inhibiting NF-κB and SOD-1 to treat amyotrophic lateral sclerosis
WO2015142984A1 (en)	2014-03-18	2015-09-24	Washington University	Methods and compositions for red-shifted chromophore substitution for optogenetic applications
CA2957661A1 (en)	2014-08-09	2016-02-18	Kevin FLANIGAN	Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
US10842886B2 (en)	2014-10-10	2020-11-24	Research Institute At Nationwide Children's Hospital	Guided injections for AAV gene transfer to muscle
US10907130B2 (en)	2014-11-05	2021-02-02	Research Institute At Nationwide Children's Hospital	Methods and materials for producing recombinant viruses in eukaryotic microalgae
US20180008727A1 (en)	2015-01-30	2018-01-11	The Regents Of The University Of California	Spinal subpial gene delivery system
MA41451A (fr)	2015-02-04	2017-12-12	Univ Washington	Constructions anti-tau
BR112017017812A2 (pt)	2015-02-23	2018-04-10	Crispr Therapeutics Ag	materiais e métodos para tratamento de hemoglobinopatias
HK1256341A1 (zh)	2015-05-15	2019-09-20	明尼苏达大学董事会	用於治疗性递送到中枢神经系统的腺相关物
US10017832B2 (en)	2015-08-25	2018-07-10	Washington University	Compositions and methods for site specific recombination at asymmetric sites
IL258005B2 (en)	2015-09-17	2025-01-01	Res Inst Nationwide Childrens Hospital	Methods and materials for gene therapy for beta-4,1-N-acetylgalactosaminyltransferase 2
US20190048340A1 (en)	2015-09-24	2019-02-14	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
AU2016344609B2 (en)	2015-10-28	2022-05-12	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of duchenne muscular dystrophy
BR112018008971A2 (pt)	2015-11-06	2018-11-27	Crispr Therapeutics Ag	materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
KR102877920B1 (ko)	2015-11-16	2025-10-30	더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈	티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법
CN109715801B (zh)	2015-12-01	2022-11-01	克里斯普治疗股份公司	用于治疗α1抗胰蛋白酶缺乏的材料和方法
KR20180118111A (ko)	2015-12-23	2018-10-30	크리스퍼 테라퓨틱스 아게	근위축성 측색 경화증 및/또는 전두측두엽 퇴행의 치료 물질 및 방법
WO2017120589A1 (en)	2016-01-08	2017-07-13	Washington University	Compositions comprising chemerin and methods of use thereof
US20190038771A1 (en)	2016-02-02	2019-02-07	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017139381A1 (en)	2016-02-08	2017-08-17	University Of Iowa Research Foundation	Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
EP3416689B1 (en)	2016-02-18	2023-01-18	CRISPR Therapeutics AG	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017147509A1 (en)	2016-02-25	2017-08-31	Marco Colonna	Compositions comprising trem2 and methods of use thereof
JP6966463B2 (ja)	2016-02-26	2021-11-17	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	組換えウイルス産物及びｄｕｘ４エクソンスキッピングを誘導するための方法
EP3429632B1 (en)	2016-03-16	2023-01-04	CRISPR Therapeutics AG	Materials and methods for treatment of hereditary haemochromatosis
AU2017241534A1 (en)	2016-03-28	2018-10-04	The Regents Of The University Of California	Method and composition for treating neuronal hyper-excitability
CA3019832C (en)	2016-04-02	2023-05-09	Research Institute At Nationwide Children's Hospital	Modified u6 promoter system for tissue specific expression
ES2977730T3 (es)	2016-04-15	2024-08-29	Res Inst Nationwide Childrens Hospital	Administración de microARN-29 y micro-distrofina por virus adenoasociado para tratar la distrofia muscular
LT3442600T (lt)	2016-04-15	2024-05-27	Research Institute At Nationwide Children's Hospital	Su adeno virusu susijusio viruso vektoriaus iš β-sarkoglikano ir mikro- rnr-29 pristatymas ir raumenų distrofijos gydymas
AU2017252023B2 (en)	2016-04-18	2024-05-02	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
US11174469B2 (en)	2016-06-29	2021-11-16	Crispr Therapeutics Ag	Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
EP4484443A3 (en)	2016-06-29	2025-03-26	CRISPR Therapeutics AG	Materials and methods for treatment of friedreich ataxia and other related disorders
CN109843914B (zh)	2016-07-06	2024-03-15	沃泰克斯药物股份有限公司	用于治疗疼痛相关病症的材料和方法
JP7305534B2 (ja)	2016-07-06	2023-07-10	バーテックスファーマシューティカルズインコーポレイテッド	疼痛関連障害を処置するための物質及び方法
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
JP2020500928A (ja)	2016-11-15	2020-01-16	リジェネクスバイオインコーポレイテッド	Ｍｐｓｉおよびｍｐｓｉｉならびに他の神経障害において神経機能を改善するための方法
JP7106534B2 (ja)	2016-11-17	2022-07-26	ネイションワイドチルドレンズホスピタル，インコーポレイテッド	メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達
JP2020500552A (ja)	2016-11-23	2020-01-16	グリットストーンオンコロジーインコーポレイテッド	新生抗原のウイルスによる送達方法
CN110191955B (zh)	2016-12-13	2024-05-31	西雅图儿童医院（Dba西雅图儿童研究所）	在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
US11142775B2 (en)	2017-01-13	2021-10-12	University Of Iowa Research Foundation	Bocaparvovirus small noncoding RNA and uses thereof
KR102719587B1 (ko)	2017-02-17	2024-10-17	론자 리미티드	아데노-관련 바이러스 생산을 위한 포유동물 세포
EP3585900B1 (en)	2017-02-22	2022-12-21	CRISPR Therapeutics AG	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585898A1 (en)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
EP3585807A1 (en)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
EP3585895A1 (en)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Compositions and methods for gene editing
WO2018154459A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
EP3596112A2 (en)	2017-03-17	2020-01-22	Newcastle University	Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
JP7676111B2 (ja)	2017-03-17	2025-05-14	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達
BR112019019833A2 (pt)	2017-03-24	2020-04-22	The University Court Of The University Of Edinburgh	terapia baseada em mecp2
EP3634449A4 (en)	2017-05-08	2021-03-17	Gritstone Oncology, Inc.	ALPHAVIRUS NEOANTIGEN VECTORS
MX2019013514A (es)	2017-05-12	2020-01-20	Crispr Therapeutics Ag	Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
WO2019011817A1 (en)	2017-07-08	2019-01-17	Genethon	TREATMENT OF SPINAL AMYOTROPHY
CN110892064A (zh)	2017-07-25	2020-03-17	牛津遗传学有限公司	腺病毒载体
AU2018345772B2 (en)	2017-10-02	2025-04-17	Research Institute At Nationwide Children's Hospital	MiRNA detargeting system for tissue specific interference
MA50833A (fr)	2017-10-17	2020-08-26	Bayer Healthcare Llc	Compositions et méthodes pour l'édition génique pour l'hémophilie a
MA50836A (fr)	2017-10-18	2020-08-26	Res Inst Nationwide Childrens Hospital	Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique de muscles pour traiter la dystrophie musculaire
US11926653B2 (en)	2017-10-20	2024-03-12	Research Institute At Nationwide Children's Hospital	Methods and materials for NT-3 gene therapy
MA50849A (fr)	2017-10-26	2020-09-02	Vertex Pharma	Substances et procédés pour le traitement d'hémoglobinopathies
WO2019094253A1 (en)	2017-11-08	2019-05-16	Avexis Inc.	Means and method for preparing viral vectors and uses of same
EP3707155A2 (en)	2017-11-09	2020-09-16	Vertex Pharmaceuticals Incorporated	Crispr/cas systems for treatment of dmd
CA3082450A1 (en)	2017-11-21	2019-05-31	Crispr Therapeutics Ag	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
JP2021506251A (ja)	2017-12-14	2021-02-22	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系、ならびにゲノム編集および他の適用におけるその使用
WO2019123430A1 (en)	2017-12-21	2019-06-27	Casebia Therapeutics Llp	Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
AU2018393050A1 (en)	2017-12-21	2020-06-18	Bayer Healthcare Llc	Materials and methods for treatment of Usher Syndrome Type 2A
MX2020007077A (es)	2018-01-04	2020-10-28	Iconic Therapeutics Inc	Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CA3088180A1 (en)	2018-01-12	2019-07-18	Crispr Therapeutics Ag	Compositions and methods for gene editing by targeting transferrin
AR114350A1 (es)	2018-01-31	2020-08-26	Res Institute At Nationwide ChildrenS Hospital	Terapia genética para la distrofia muscular de cinturas del tipo 2c
US11268077B2 (en)	2018-02-05	2022-03-08	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
US11566236B2 (en)	2018-02-05	2023-01-31	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
MA51869A (fr)	2018-02-16	2020-12-23	Bayer Healthcare Llc	Compositions et méthodes pour l'édition génique par ciblage du fibrinogène-alpha
MA52074A (fr)	2018-03-19	2021-01-27	Bayer Healthcare Llc	Nouveaux systèmes d'endonucléase à arn programmable et leurs utilisations
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
WO2019210057A1 (en)	2018-04-27	2019-10-31	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Rapamycin resistant cells
AU2019275072A1 (en)	2018-05-23	2021-01-21	Seattle Project Corp.	Shared antigens
EP3801638A1 (en)	2018-06-08	2021-04-14	Novartis AG	Cell-based assay for measuring drug product potency
GB201809588D0 (en)	2018-06-12	2018-07-25	Univ Bristol	Materials and methods for modulating intraocular and intracranial pressure
EP3807309A1 (en)	2018-06-18	2021-04-21	Research Institute at Nationwide Children's Hospital	Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
MY208145A (en)	2018-06-18	2025-04-18	Res Inst Nationwide Childrens Hospital	Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
KR20210028162A (ko)	2018-06-29	2021-03-11	더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈	지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법
JP2021534755A (ja)	2018-08-22	2021-12-16	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	筋強直性ジストロフィープロテインキナーゼの発現を抑制および／またはｄｍｐｋ遺伝子の３’非翻訳領域におけるトリヌクレオチドリピート伸長に干渉するための組換えウイルス産物および方法
WO2020047268A1 (en)	2018-08-29	2020-03-05	Research Institute At Nationwide Children's Hospital	Products and methods for inhibition of expression of mutant gars protein
CN111315407B (zh)	2018-09-11	2023-05-02	上海市公共卫生临床中心	一种广谱抗流感疫苗免疫原及其应用
JP7520826B2 (ja)	2018-10-17	2024-07-23	クリスパー・セラピューティクス・アクチェンゲゼルシャフト	導入遺伝子を送達するための組成物および方法
CN113710799B (zh)	2018-11-28	2024-11-12	克里斯珀医疗股份公司	用于在LNP中使用的编码CAS9的优化mRNA
CN120860258A (zh)	2018-11-30	2025-10-31	北京诺华制药有限公司	Aav病毒载体及其用途
CN113474459A (zh)	2018-12-21	2021-10-01	吉尼松公司	用于基因疗法载体的表达盒
EP3906308A1 (en)	2018-12-31	2021-11-10	Research Institute at Nationwide Children's Hospital	Dux4 rna silencing using rna targeting crispr-cas13b
CA3129077A1 (en)	2019-02-04	2020-08-13	Research Institute At Nationwide Children's Hospital	Adeno-associated virus delivery of cln3 polynucleotide
JP2022519597A (ja)	2019-02-04	2022-03-24	リサーチ・インスティチュート・アット・ネーションワイド・チルドレンズ・ホスピタル	Ｃｌｎ６ポリヌクレオチドのアデノ随伴ウイルス送達
SG11202108357PA (en)	2019-02-15	2021-08-30	Crispr Therapeutics Ag	Gene editing for hemophilia a with improved factor viii expression
SG11202108044YA (en)	2019-02-25	2021-09-29	Novartis Ag	Compositions and methods to treat bietti crystalline dystrophy
US20220154211A1 (en)	2019-02-25	2022-05-19	Novartis Ag	Compositions and methods to treat bietti crystalline dystrophy
AU2020229340A1 (en)	2019-02-26	2021-09-16	Research Institute At Nationwide Children's Hospital	Adeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy
SG11202109741VA (en)	2019-03-12	2021-10-28	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
EP3947700A4 (en)	2019-04-01	2023-01-04	Tenaya Therapeutics, Inc.	Adeno-associated virus with engineered capsid
CA3137080A1 (en)	2019-04-15	2020-10-22	Sanford Research	Gene therapy for treating or preventing visual effects in batten disease
CN114641318A (zh)	2019-04-15	2022-06-17	衣阿华大学研究基金会	用于治疗囊性纤维化的组合物和方法
BR112021020706A2 (pt)	2019-04-15	2022-03-15	Spirovant Sciences Inc	Métodos e composições para expressão de transgene
US20210047649A1 (en)	2019-05-08	2021-02-18	Vertex Pharmaceuticals Incorporated	Crispr/cas all-in-two vector systems for treatment of dmd
US20220233655A1 (en)	2019-05-17	2022-07-28	Research Institute At Nationwide Children's Hospital	Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme
MX2021014525A (es)	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.
MA56393A (fr)	2019-06-28	2022-05-04	Bayer Healthcare Llc	Matériels et méthodes de régulation de l'édition de gènes
EP4004213A1 (en)	2019-07-25	2022-06-01	Novartis AG	Regulatable expression systems
RS65421B1 (sr)	2019-08-21	2024-05-31	Res Inst Nationwide Childrens Hospital	Isporuka adeno-asociranog virusnog vektora alfa-sarkoglikana i lečenje mišićne distrofije
US20230416776A1 (en)	2019-10-08	2023-12-28	Regents Of The University Of Minnesota	Crispr-mediated human genome editing with vectors
CA3158131A1 (en)	2019-10-18	2021-04-22	Nicolas Sebastien Wein	Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene
AU2020366531A1 (en)	2019-10-18	2022-05-26	Research Institute At Nationwide Children's Hospital	Gene therapy targeting cochlear cells
AU2020385387A1 (en)	2019-11-22	2022-06-02	Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico	Materials and methods for treatment of disorders associated with the IGHMBP2 gene
CN115516100A (zh)	2019-12-20	2022-12-23	全国儿童医院研究所	靶向肌肉疾病中肌肉的优化基因疗法
US20230090989A1 (en)	2020-02-18	2023-03-23	Research Institute At Nationwide Children's Hospital	AAV-Mediated Targeting of MIRNA in the Treatment of X-Linked Disorders
JP2023523573A (ja)	2020-04-14	2023-06-06	ジェネトン	酸性セラミダーゼ欠乏症を処置するためのベクター
IL299094A (en)	2020-06-15	2023-02-01	Res Inst Nationwide Childrens Hospital	Administration of an adeno-associated virus vector for muscular dystrophies
WO2022006253A2 (en)	2020-06-30	2022-01-06	University Of Iowa Research Foundation	Methods and compositions for administering recombinant viral vectors
WO2022011099A1 (en)	2020-07-08	2022-01-13	Regents Of The University Of Minnesota	Modified hexosaminidase and uses thereof
WO2022018638A1 (en)	2020-07-21	2022-01-27	Crispr Therapeutics Ag	Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
US12054738B2 (en)	2020-07-30	2024-08-06	Shape Therapeutics Inc.	Stable cell lines for inducible production of rAAV virions
CN116438308A (zh)	2020-08-06	2023-07-14	磨石生物公司	多表位疫苗盒
WO2022047201A1 (en)	2020-08-27	2022-03-03	University Of Iowa Research Foundation	Gene knock-out for treatment of glaucoma
TWI887479B (zh)	2020-09-08	2025-06-21	美商薩羅塔治療公司	表現γ-肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
AU2021345112A1 (en)	2020-09-15	2023-04-27	Research Institute At Nationwide Children's Hospital	Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
AU2021349277A1 (en)	2020-09-28	2023-05-11	Research Institute At Nationwide Children's Hospital	Products and methods for treating muscular dystrophy
EP4222264A1 (en)	2020-09-30	2023-08-09	CRISPR Therapeutics AG	Materials and methods for treatment of amyotrophic lateral sclerosis
BR112023006305A2 (pt)	2020-10-09	2023-05-09	Tenaya Therapeutics Inc	Métodos e composições de terapia gênica com placofilina-2
IL303230A (en)	2020-11-30	2023-07-01	Res Inst Nationwide Childrens Hospital	Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
WO2022133246A1 (en)	2020-12-17	2022-06-23	Vertex Pharmaceuticals Incorporated	Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
AU2022212922A1 (en)	2021-01-27	2023-08-17	Research Institute At Nationwide Children's Hospital	Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
US20240093191A1 (en)	2021-02-03	2024-03-21	Research Institute At Nationwide Children's Hospital	Compositions and methods for treating disease associated with dux4 overexpression
WO2022170038A1 (en)	2021-02-05	2022-08-11	Amicus Therapeutics, Inc.	Adeno-associated virus delivery of cln3 polynucleotide
WO2022170082A1 (en)	2021-02-05	2022-08-11	Regents Of The University Of Minnesota	Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses
US20240254509A1 (en)	2021-03-04	2024-08-01	Research Institute At Nationwide Children's Hospital	Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
EP4305157A1 (en)	2021-03-09	2024-01-17	Huidagene Therapeutics (Singapore) Pte. Ltd.	Engineered crispr/cas13 system and uses thereof
WO2022221424A1 (en)	2021-04-13	2022-10-20	Research Institute At Nationwide Children's Hospital	Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery
WO2022221684A1 (en)	2021-04-15	2022-10-20	Spirovant Sciences, Inc.	Methods and compositions for treatment of cystic fibrosis
US12275941B2 (en)	2021-04-15	2025-04-15	Research Institute At Nationwide Children's Hospital	Products and methods for inhibition of expression of dynamin-1 variants
AU2022262420A1 (en)	2021-04-23	2023-11-16	Research Institute At Nationwide Children's Hospital	Products and methods for treating muscular dystrophy
US20240425877A1 (en)	2021-05-07	2024-12-26	Ucl Business Ltd	Abca4 genome editing
AU2022279062A1 (en)	2021-05-17	2024-01-04	Sarepta Therapeutics, Inc.	Production of recombinant aav vectors for treating muscular dystrophy
EP4108263A3 (en)	2021-06-02	2023-03-22	Research Institute at Nationwide Children's Hospital	Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
EP4101928A1 (en)	2021-06-11	2022-12-14	Bayer AG	Type v rna programmable endonuclease systems
AU2022290382A1 (en)	2021-06-11	2023-11-23	Bayer Aktiengesellschaft	Type v rna programmable endonuclease systems
WO2023283962A1 (en)	2021-07-16	2023-01-19	Huigene Therapeutics Co., Ltd.	Modified aav capsid for gene therapy and methods thereof
WO2023018854A2 (en)	2021-08-11	2023-02-16	Solid Biosciences Inc.	Treatment of muscular dystrophy
EP4144841A1 (en)	2021-09-07	2023-03-08	Bayer AG	Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
WO2023042104A1 (en)	2021-09-16	2023-03-23	Novartis Ag	Novel transcription factors
EP4413131A1 (en)	2021-10-07	2024-08-14	Research Institute at Nationwide Children's Hospital	Products and methods for myelin protein zero silencing and treating cmt1b disease
EP4413376A1 (en)	2021-10-08	2024-08-14	Amicus Therapeutics, Inc.	Biomarkers for lysosomal storage diseases
EP4219726A1 (en)	2021-10-15	2023-08-02	Research Institute at Nationwide Children's Hospital	Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
EP4186919A1 (en)	2021-11-30	2023-05-31	Research Institute at Nationwide Children's Hospital	Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
EP4198046A1 (en)	2021-12-16	2023-06-21	Genethon	Alpha-sarcoglycan gene transfer increase using modified itr sequences
EP4198134A1 (en)	2021-12-16	2023-06-21	Genethon	Gamma-sarcoglycan gene transfer increase using modified itr sequences
EP4198047A1 (en)	2021-12-16	2023-06-21	Genethon	Fukutin related protein gene transfer increase using modified itr sequences
EP4198048A1 (en)	2021-12-16	2023-06-21	Genethon	Calpain-3 gene transfer increase using modified itr sequences
AU2022420596A1 (en)	2021-12-21	2024-07-11	Research Institute At Nationwide Children's Hospital	Materials and methods for the treatment of limb girdle muscular dystrophy
EP4453191A1 (en)	2021-12-23	2024-10-30	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2023166425A1 (en)	2022-03-01	2023-09-07	Crispr Therapeutics Ag	Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
AU2023227586A1 (en)	2022-03-03	2024-09-12	Research Institute At Nationwide Children's Hospital	Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
IL316038A (en)	2022-04-04	2024-11-01	Univ California	Preparations and methods for genetic complementation
WO2023201207A1 (en)	2022-04-11	2023-10-19	Tenaya Therapeutics, Inc.	Adeno-associated virus with engineered capsid
US20250353883A1 (en)	2022-05-06	2025-11-20	Novartis Ag	Novel recombinant aav vp2 fusion polypeptides
US20250340887A1 (en)	2022-06-08	2025-11-06	Research Institute At Nationwide Children's Hospital	Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
CN119403922A (zh)	2022-06-10	2025-02-07	拜耳公司	新的小型v型rna可编程内切核酸酶系统
JP2025524569A (ja)	2022-07-06	2025-07-30	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	Ｃｌｎ１ポリヌクレオチドのアデノ随伴ウイルス送達
WO2024035782A1 (en)	2022-08-10	2024-02-15	Aav Gene Therapeutics, Inc.	Aav-mediated intramuscular delivery of insulin
EP4590838A1 (en)	2022-09-23	2025-07-30	Sarepta Therapeutics, Inc.	Recombinant aav vectors for treating muscular dystrophy
WO2024081706A1 (en)	2022-10-11	2024-04-18	Research Institute At Nationwide Children's Hospital	Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
WO2024086747A1 (en)	2022-10-19	2024-04-25	Affinia Therapeutics Inc.	Recombinant aavs with improved tropism and specificity
WO2024092171A1 (en)	2022-10-26	2024-05-02	University Of Iowa Research Foundation	Method to deliver large genes using virus and a dna recombination system
EP4608856A1 (en)	2022-10-27	2025-09-03	CARGO Therapeutics, Inc.	Compositions and methods for improved immunotherapies
IL321270A (en)	2022-12-13	2025-08-01	Bayer Ag	Engineered RNA-type programmable endonucleases and their uses
WO2024151982A1 (en)	2023-01-13	2024-07-18	Amicus Therapeutics, Inc.	Gene therapy constructs for the treatment of pompe disease
IL322049A (en)	2023-02-01	2025-09-01	Sarepta Therapeutics Inc	Methods for producing raav
WO2024168276A2 (en)	2023-02-09	2024-08-15	Cargo Therapeutics, Inc.	Compositions and methods for immunotherapies
EP4698558A2 (en)	2023-04-18	2026-02-25	Research Institute at Nationwide Children's Hospital, Inc.	Gene therapy for treating limb girdle muscular dystrophy r9 and congenital muscular dystrophy 1c
WO2024229115A1 (en)	2023-05-02	2024-11-07	Research Institute At Nationwide Children's Hospital	Treatment of multiple sclerosis using nt-3 gene therapy
WO2024229259A1 (en)	2023-05-02	2024-11-07	Research Institute At Nationwide Children's Hospital	Gene therapy for treatment of protein misfolding diseases
WO2024229211A2 (en)	2023-05-02	2024-11-07	Research Institute At Nationwide Children's Hospital	A modular system to convert therapeutic microrna expression cassettes from polymerase iii-based to polymerase ii-based promoters
WO2024238807A2 (en)	2023-05-16	2024-11-21	Affinia Therapeutics Inc.	Recombinant aavs with improved tropism and specificity
IL325133A (en)	2023-06-07	2026-02-01	Res Inst Nationwide Childrens Hospital	Gene therapy for lysosomal acid lipase deficiency (LAL-D)
AU2024305531A1 (en)	2023-06-13	2026-01-22	Research Institute At Nationwide Children's Hospital	Materials and methods for the treatment of neurofibromin 1 mutations and diseases resulting therefrom
AU2024301706A1 (en)	2023-07-21	2026-02-05	Crispr Therapeutics Ag	Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
EP4512403A1 (en)	2023-08-22	2025-02-26	Friedrich-Schiller-Universität Jena	Neuropeptide b and w-receptor as a target for treating mood disorders and/or chronic stress
WO2025076291A1 (en)	2023-10-06	2025-04-10	Bluerock Therapeutics Lp	Engineered type v rna programmable endonucleases and their uses
WO2025096498A1 (en)	2023-10-30	2025-05-08	Research Institute At Nationwide Children's Hospital	Compositions and methods for treating diseases or conditions associated with progerin expression
WO2025179121A1 (en)	2024-02-21	2025-08-28	Research Institute At Nationwide Children's Hospital	Exon 17-targeted nucleic acids, compositions, and methods for treatment of dystrophin-based myopathies
WO2025186726A1 (en)	2024-03-05	2025-09-12	Crispr Therapeutics Ag	Modulating expression of agt (angiotensinogen) gene
WO2025188993A2 (en)	2024-03-07	2025-09-12	Research Institute At Nationwide Children's Hospital	Gene therapy for treating gne-related disorders
WO2025194042A1 (en)	2024-03-14	2025-09-18	Affinia Therapeutics Inc.	Plasmid system for production of recombinant adenoassociated virus
WO2025212838A1 (en)	2024-04-03	2025-10-09	Research Institute At Nationwide Children's Hospital	Products and methods for treating diseases or disorders associated with dux4 overexpression
WO2025226343A1 (en)	2024-04-26	2025-10-30	Research Institute At Nationwide Children's Hospital	Products and methods to inhibit expression of dynamin-1 variants and replace dynamin-1
WO2025227063A1 (en)	2024-04-26	2025-10-30	Affinia Therapeutics Inc.	Recombinant aavs with improved tropism and specificity
WO2025235425A1 (en)	2024-05-06	2025-11-13	Research Institute At Nationwide Children's Hospital	Improved proviral plasmids
WO2025235491A1 (en)	2024-05-07	2025-11-13	Affinia Therapeutics Inc.	Recombinant aav for treatment of cardiac diseases
WO2025240690A2 (en)	2024-05-15	2025-11-20	Research Institute At Nationwide Children's Hospital	Products and methods for treating diseases or conditions associated with progerin expression from an aberrant lmna gene
WO2025250909A1 (en)	2024-05-31	2025-12-04	Sarepta Therapeutics, Inc.	Muscle-tropic recombinant aav
WO2026028089A1 (en)	2024-07-29	2026-02-05	Novartis Ag	Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4797368A (en) *	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en) *	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5141742A (en) *	1986-02-07	1992-08-25	Oncogen	Vaccines against melanoma
WO1991018088A1 (en) *	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) *	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
DE4436664A1 (de) *	1994-10-13	1996-07-04	Max Planck Gesellschaft	Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen

1994
- 1994-11-03 PT PT95900505T patent/PT728214E/pt unknown
- 1994-11-03 DE DE69433922T patent/DE69433922T2/de not_active Expired - Fee Related
- 1994-11-03 EP EP95900505A patent/EP0728214B1/en not_active Expired - Lifetime
- 1994-11-03 ES ES95900505T patent/ES2220923T3/es not_active Expired - Lifetime
- 1994-11-03 WO PCT/US1994/012582 patent/WO1995013392A1/en not_active Ceased
- 1994-11-03 CA CA002176215A patent/CA2176215C/en not_active Expired - Fee Related
- 1994-11-03 AT AT95900505T patent/ATE272123T1/de not_active IP Right Cessation
- 1994-11-03 US US08/362,608 patent/US5837484A/en not_active Expired - Fee Related
- 1994-11-03 DK DK95900505T patent/DK0728214T3/da active
- 1994-11-03 JP JP51387495A patent/JP3952312B2/ja not_active Expired - Fee Related
- 1994-11-03 AU AU81309/94A patent/AU678867B2/en not_active Ceased

Also Published As

Publication number	Publication date
CA2176215C (en)	2007-06-26
DE69433922D1 (de)	2004-09-02
AU678867B2 (en)	1997-06-12
EP0728214B1 (en)	2004-07-28
AU8130994A (en)	1995-05-29
CA2176215A1 (en)	1995-05-18
ATE272123T1 (de)	2004-08-15
ES2220923T3 (es)	2004-12-16
DE69433922T2 (de)	2005-07-28
DK0728214T3 (da)	2004-11-29
EP0728214A4 (en)	1997-02-12
EP0728214A1 (en)	1996-08-28
US5837484A (en)	1998-11-17
WO1995013392A1 (en)	1995-05-18
JP3952312B2 (ja)	2007-08-01
JPH09510602A (ja)	1997-10-28

Publication	Publication Date	Title
PT728214E (pt)	2004-11-30	Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
MX9709549A (es)	1998-03-31	Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen.
AU7497494A (en)	1995-02-28	Recombinant vector containing a sequence of a lipoprotein gene for the expression of nucleotide sequences
AU1539595A (en)	1995-08-15	Process for preparing recombinant adeno-associated viruses (AAVs), and uses
WO1993024641A3 (en)	1994-05-11	Adeno-associated virus with inverted terminal repeat sequences as promoter
EP0733103A4 (en)	1997-12-17	ACHIEVING HIGH TITERS OF THE RECOMBINANT AAV VECTOR
AU1189195A (en)	1995-06-27	Recombinant protein production in bovine adenovirus expression vector system
CA2120514A1 (en)	1993-04-15	Synthetic dna sequence having enhanced insecticidal activity in maize
DE69535703D1 (de)	2008-03-27	Aav-vermittelte überbringung von dna in zellen des nervensystems
EP0706319A4 (en)	1998-04-22	RETROVIRAL VECTORS WITH THE ABILITY TO EXPRESS MULTIMERAL PROTEINS FROM MULTIPLE TRANSLATION INITIATION LOCATIONS
EP0718400A3 (en)	1996-07-03	Methods and compositions for controlling translation of HCV proteins
HU9202458D0 (en)	1992-10-28	Expressing systems
CA2304105A1 (en)	1999-04-01	Control pod dehiscence or shatter
WO1998055639A3 (fr)	1999-03-04	Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
WO1996001317A3 (en)	1996-04-18	Mammalian peroxisome proliferator-activated receptors and uses thereof
WO1994013812A3 (en)	1994-11-10	Novel entomopoxvirus genes, proteins and methods of use thereof
IL117194A0 (en)	1996-06-18	Amplifying sequences vectors comprising them and their uses in compositions for the expression of nucleotide sequences and pharmaceutical compositions containing them
DE69632201D1 (de)	2004-05-19	Regulierte expression von proteinen in stabil transformierten säugetierzellen
HUP9802587A2 (hu)	1999-02-01	Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
CA2033069A1 (en)	1990-11-20	Saf polypeptide, gene, promoter and use for expression in streptomyces
DK0528925T3 (da)	1994-10-24	Klonings- og/eller ekspressionsvektorer, deres fremstilling og anvendelse
GB2318793A (en)	1998-05-06	Mpt83 gene from mycobacterium tuberculosis
AU5110390A (en)	1990-09-13	Cdna coding for placental protein 9 (pp9), the isolation and use thereof
MX9605938A (es)	1998-05-31	Promotor de actinomicetos.